Walter Hanel

1.4k total citations
39 papers, 910 citations indexed

About

Walter Hanel is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Walter Hanel has authored 39 papers receiving a total of 910 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 19 papers in Oncology and 16 papers in Immunology. Recurrent topics in Walter Hanel's work include Lymphoma Diagnosis and Treatment (25 papers), Chronic Lymphocytic Leukemia Research (7 papers) and CAR-T cell therapy research (7 papers). Walter Hanel is often cited by papers focused on Lymphoma Diagnosis and Treatment (25 papers), Chronic Lymphocytic Leukemia Research (7 papers) and CAR-T cell therapy research (7 papers). Walter Hanel collaborates with scholars based in United States, Canada and India. Walter Hanel's co-authors include Ute M. Moll, N D Marchenko, Sarah L. Gaffen, Stephen Yu, Wen-Kai Weng, Suheng Xu, Amarnath Maitra, Narendranath Epperla, David Swart and Joel Tocker and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Walter Hanel

34 papers receiving 900 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Walter Hanel United States 12 436 418 287 225 165 39 910
Lorraine Tracey Spain 15 321 0.7× 580 1.4× 216 0.8× 266 1.2× 181 1.1× 20 1.1k
Alyssa Bouska United States 14 437 1.0× 413 1.0× 129 0.4× 102 0.5× 199 1.2× 30 695
Anagh A. Sahasrabuddhe United States 16 217 0.5× 521 1.2× 224 0.8× 128 0.6× 261 1.6× 23 926
Carol M. Amato United States 16 368 0.8× 616 1.5× 268 0.9× 327 1.5× 87 0.5× 34 1.0k
E B Bröcker Germany 19 442 1.0× 653 1.6× 614 2.1× 197 0.9× 270 1.6× 27 1.5k
Samir Tawadros Germany 16 225 0.5× 254 0.6× 352 1.2× 69 0.3× 100 0.6× 34 863
G W Krissansen New Zealand 16 202 0.5× 473 1.1× 403 1.4× 192 0.9× 99 0.6× 28 1.1k
Jessica Dal Col Italy 20 554 1.3× 469 1.1× 550 1.9× 125 0.6× 202 1.2× 35 1.2k
Raphael Koch Germany 11 334 0.8× 753 1.8× 259 0.9× 375 1.7× 210 1.3× 33 1.2k
Evelien Schaafsma United States 13 336 0.8× 226 0.5× 294 1.0× 140 0.6× 115 0.7× 30 801

Countries citing papers authored by Walter Hanel

Since Specialization
Citations

This map shows the geographic impact of Walter Hanel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter Hanel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter Hanel more than expected).

Fields of papers citing papers by Walter Hanel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter Hanel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter Hanel. The network helps show where Walter Hanel may publish in the future.

Co-authorship network of co-authors of Walter Hanel

This figure shows the co-authorship network connecting the top 25 collaborators of Walter Hanel. A scholar is included among the top collaborators of Walter Hanel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walter Hanel. Walter Hanel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Assouline, Sarit, Amitkumar Mehta, Walter Hanel, et al.. (2025). Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 788–799.e11. 1 indexed citations
2.
Tsyba, Liudmyla, Neeraj Jain, Lalit Sehgal, et al.. (2025). Targeting the DNA damage response through TBL1X in mantle cell lymphoma. Blood Advances. 9(8). 2006–2018. 1 indexed citations
3.
Brammer, Jonathan E., Zachary Braunstein, Patrick Stevens, et al.. (2025). Targeting the methylome in T-LGL leukemia: Pre-clinical analysis and Results of a Phase I trial with oral 5-azacytidine. Blood. 146(Supplement 1). 890–890.
4.
Reneau, John, et al.. (2024). Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas. Blood. 144(Supplement 1). 4438–4438. 1 indexed citations
5.
6.
Braunstein, Zachary, Eric McLaughlin, Walter Hanel, et al.. (2023). Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas. Leukemia & lymphoma. 65(3). 301–311. 1 indexed citations
7.
Grover, Natalie S., Pallawi Torka, Marcus P. Watkins, et al.. (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Advances. 7(22). 6839–6843. 3 indexed citations
8.
Xu‐Monette, Zijun Y., Krysta M. Coyle, Laura K. Hilton, et al.. (2023). Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 37(10). 2094–2106. 4 indexed citations
9.
Chan, Wing Keung, Jessica Williams, Zehua Bian, et al.. (2023). A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Experimental Hematology and Oncology. 12(1). 79–79. 9 indexed citations
10.
Faisal, Muhammad Salman, Walter Hanel, Timothy Voorhees, et al.. (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Medicine. 12(7). 8228–8237. 2 indexed citations
11.
Nalin, Ansel P., Qiuhong Zhao, Timothy Voorhees, et al.. (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia. Frontiers in Oncology. 13. 1264387–1264387. 1 indexed citations
12.
Bharti, Vijaya, Amrendra Kumar, Rebecca L. Shattuck-Brandt, et al.. (2022). BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Reports. 41(12). 111826–111826. 29 indexed citations
13.
Hanel, Walter, Alex F. Herrera, & Narendranath Epperla. (2022). Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. Experimental Hematology and Oncology. 11(1). 108–108. 7 indexed citations
14.
Hanel, Walter, Youssef Youssef, Liudmyla Tsyba, et al.. (2022). A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells. Experimental Hematology and Oncology. 11(1). 40–40. 4 indexed citations
15.
Hanel, Walter & Narendranath Epperla. (2020). Emerging therapies in mantle cell lymphoma. Journal of Hematology & Oncology. 13(1). 79–79. 36 indexed citations
16.
Hanel, Walter, N D Marchenko, Suheng Xu, et al.. (2013). Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death and Differentiation. 20(7). 898–909. 219 indexed citations
17.
Hanel, Walter & Ute M. Moll. (2011). Links between mutant p53 and genomic instability. Journal of Cellular Biochemistry. 113(2). 433–439. 144 indexed citations
18.
Onishi, Reiko, et al.. (2010). SEF/IL-17R (SEFIR) Is Not Enough. Journal of Biological Chemistry. 285(43). 32751–32759. 43 indexed citations
19.
Marchenko, N D, Walter Hanel, Dun Li, et al.. (2009). Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding. Cell Death and Differentiation. 17(2). 255–267. 95 indexed citations
20.
Kramer, Jill M., Walter Hanel, Fang Shen, et al.. (2007). Cutting Edge: Identification of a Pre-Ligand Assembly Domain (PLAD) and Ligand Binding Site in the IL-17 Receptor. The Journal of Immunology. 179(10). 6379–6383. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lorraine Tracey Breakdown of academic impact, for papers by Alyssa Bouska Breakdown of academic impact, for papers by Anagh A. Sahasrabuddhe Breakdown of academic impact, for papers by Carol M. Amato Breakdown of academic impact, for papers by E B Bröcker Breakdown of academic impact, for papers by Samir Tawadros Breakdown of academic impact, for papers by G W Krissansen Breakdown of academic impact, for papers by Jessica Dal Col Breakdown of academic impact, for papers by Raphael Koch Breakdown of academic impact, for papers by Evelien Schaafsma
Rankless by CCL
2026